{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:15:56Z","timestamp":1783401356021,"version":"3.54.6"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10067-026-08152-5","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:54:58Z","timestamp":1781643298000},"page":"4625-4634","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk management plan adherence and clinical outcomes in patients receiving targeted therapies"],"prefix":"10.1007","volume":"45","author":[{"given":"Li-Fong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiu-Lan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8446-7936","authenticated-orcid":false,"given":"Yi-Hsien","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Hao","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"8152_CR1","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388:2023\u20132038","journal-title":"Lancet"},{"key":"8152_CR2","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.ard.2025.02.009","volume":"84","author":"KL Winthrop","year":"2025","unstructured":"Winthrop KL, Bathon J, Kerschbaumer A, Isaacs JD, Mease P, Gottenberg JE et al (2025) Chasing the target: reports from the Advances in Targeted Therapies meeting, 2024. Ann Rheum Dis 84:927\u2013936","journal-title":"Ann Rheum Dis"},{"key":"8152_CR3","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1136\/ard-2022-223335","volume":"82","author":"GE Fragoulis","year":"2023","unstructured":"Fragoulis GE, Nikiphorou E, Dey M, Zhao SS, Courvoisier DS, Arnaud L et al (2023) 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 82:742\u2013753","journal-title":"Ann Rheum Dis"},{"key":"8152_CR4","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL et al (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 386:316\u2013326","journal-title":"N Engl J Med"},{"key":"8152_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landewe RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D et al (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 82:3\u201318","journal-title":"Ann Rheum Dis"},{"key":"8152_CR6","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/nrrheum.2010.154","volume":"6","author":"T Takeuchi","year":"2010","unstructured":"Takeuchi T, Kameda H (2010) The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 6:644\u2013652","journal-title":"Nat Rev Rheumatol"},{"key":"8152_CR7","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2025.039","volume":"17","author":"U Testa","year":"2025","unstructured":"Testa U, Castelli G, Pelosi E, Galli E, Chiusolo P (2025) Toxicities associated with CAR-T cell therapies. Mediterr J Hematol Infect Dis 17:e2025039","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"8152_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103267","volume":"84","author":"Y Zhu","year":"2025","unstructured":"Zhu Y, Liu K, Rosen ST, Liu W, Zhu H (2025) Treatment-related adverse events of chimeric antigen receptor-T therapies for cancers in clinical trials: a systematic review and meta-analysis. EClinicalMedicine 84:103267","journal-title":"EClinicalMedicine"},{"key":"8152_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.39480","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC et al (2016) 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 68:1\u201326","journal-title":"Arthritis Rheumatol"},{"key":"8152_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jmii.2017.04.002","volume":"52","author":"CT Lin","year":"2019","unstructured":"Lin CT, Huang WN, Hsieh CW, Chen YM, Chen DY, Hsieh TY et al (2019) Safety and effectiveness of tocilizumab in treating patients with rheumatoid arthritis: a three-year study in Taiwan. J Microbiol Immunol Infect 52:141\u2013150","journal-title":"J Microbiol Immunol Infect"},{"key":"8152_CR11","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/art.41752","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K et al (2021) 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 73:1108\u20131123","journal-title":"Arthritis Rheumatol"},{"key":"8152_CR12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/acr.25045","volume":"75","author":"AR Bass","year":"2023","unstructured":"Bass AR, Chakravarty E, Akl EA, Bingham CO, Calabrese L, Cappelli LC et al (2023) 2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases. Arthritis Care Res (Hoboken) 75:449\u2013464","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"8152_CR13","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1007\/s10067-021-05660-4","volume":"40","author":"HC Hsu","year":"2021","unstructured":"Hsu HC, Chang YS, Hou TY, Chen LF, Hu LF, Lin TM et al (2021) Pneumocystis jirovecii pneumonia in autoimmune rheumatic diseases: a nationwide population-based study. Clin Rheumatol 40:3755\u20133763","journal-title":"Clin Rheumatol"},{"key":"8152_CR14","doi-asserted-by":"crossref","unstructured":"Thomas CF Jr, Limper AH (2004) Pneumocystis pneumonia. N Engl J Med 350:2487\u20132498","DOI":"10.1056\/NEJMra032588"},{"key":"8152_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens10020236","volume":"10","author":"AD Gingerich","year":"2021","unstructured":"Gingerich AD, Norris KA, Mousa JJ (2021) Pneumocystis pneumonia: immunity, vaccines, and treatments. Pathogens 10:2","journal-title":"Pathogens"},{"key":"8152_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.70055","volume":"14","author":"Y Chen","year":"2025","unstructured":"Chen Y, Rong H, Li T, Zhang C, Yang H, Sun H et al (2025) T-cell subsets in Pneumocystis pneumonia. Clin Transl Immunol 14:e70055","journal-title":"Clin Transl Immunol"},{"key":"8152_CR17","doi-asserted-by":"publisher","first-page":"6147","DOI":"10.4049\/jimmunol.176.10.6147","volume":"176","author":"FE Lund","year":"2006","unstructured":"Lund FE, Hollifield M, Schuer K, Lines JL, Randall TD, Garvy BA (2006) B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection. J Immunol 176:6147\u20136154","journal-title":"J Immunol"},{"key":"8152_CR18","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.161450","volume":"7","author":"K Noell","year":"2022","unstructured":"Noell K, Dai G, Pungan D, Ebacher A, McCombs JE, Landry SJ et al (2022) Germline IgM predicts T cell immunity to Pneumocystis. JCI Insight 7:e17","journal-title":"JCI Insight"},{"key":"8152_CR19","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1165\/rcmb.2016-0360ED","volume":"56","author":"JK Kolls","year":"2017","unstructured":"Kolls JK (2017) An emerging role of B cell immunity in susceptibility to Pneumocystis pneumonia. Am J Respir Cell Mol Biol 56:279\u2013280","journal-title":"Am J Respir Cell Mol Biol"},{"key":"8152_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.70065","author":"EA Martino","year":"2025","unstructured":"Martino EA, Caserta S, Vigna E, Bruzzese A, Amodio N, Lucia E et al (2025) Infections in chronic lymphocytic leukemia: evolving risks and prevention strategies. Eur J Haematol. https:\/\/doi.org\/10.1111\/ejh.70065","journal-title":"Eur J Haematol"},{"key":"8152_CR21","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/ckj\/sfx038","volume":"10","author":"A Nixon","year":"2017","unstructured":"Nixon A, Ogden L, Woywodt A, Dhaygude A (2017) Infectious complications of rituximab therapy in renal disease. Clin Kidney J 10:455\u2013460","journal-title":"Clin Kidney J"},{"key":"8152_CR22","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1128\/IAI.03099-14","volume":"83","author":"W Elsegeiny","year":"2015","unstructured":"Elsegeiny W, Eddens T, Chen K, Kolls JK (2015) Anti-CD20 antibody therapy and susceptibility to Pneumocystis pneumonia. Infect Immun 83:2043\u20132052","journal-title":"Infect Immun"},{"key":"8152_CR23","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1378\/chest.12-0477","volume":"144","author":"I Martin-Garrido","year":"2013","unstructured":"Martin-Garrido I, Carmona EM, Specks U, Limper AH (2013) Pneumocystis pneumonia in patients treated with rituximab. Chest 144:258\u2013265","journal-title":"Chest"},{"key":"8152_CR24","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0140-6736(22)01349-6","volume":"400","author":"N Conrad","year":"2022","unstructured":"Conrad N, Verbeke G, Molenberghs G, Goetschalckx L, Callender T, Cambridge G et al (2022) Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. Lancet 400:733\u2013743","journal-title":"Lancet"},{"key":"8152_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1565909","volume":"16","author":"E Silvagni","year":"2025","unstructured":"Silvagni E, Bortoluzzi A, Occhino G, Bellelli G, Garaffoni C, Delvino P et al (2025) Frailty and cardiovascular safety of JAK inhibitors versus TNF inhibitors in rheumatoid arthritis: a real-world comparative study of drug effects and patient profiles. Front Pharmacol 16:1565909","journal-title":"Front Pharmacol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08152-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08152-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08152-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:28:21Z","timestamp":1783398501000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08152-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["8152"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08152-5","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"6 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The study was approved by the Institutional Review Board of Kaohsiung Veterans General Hospital (IRB No. KSVGH23-CT12-14). The need for informed consent was waived owing to the retrospective design and use of anonymized data. The study was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}